Myriad Will Acquire Rules-Based Medicine | May 9, 2011 Issue - Vol. 89 Issue 19 | Chemical & Engineering News
Volume 89 Issue 19 | p. 25 | Concentrates
Issue Date: May 9, 2011

Myriad Will Acquire Rules-Based Medicine

Department: Business
Keywords: diagnostics, genetics, biomarkers

Myriad Genetics has agreed to acquire Rules-Based Medicine for $80 million in cash. Based in Salt Lake City, Myriad is a molecular diagnostics company that markets nine products for assessing a person’s risk of developing disease. Austin, Texas-based RBM, meanwhile, discovers novel biomarkers for drug industry partners using its multiplex immunoassay technology. Myriad says the purchase will add eight product candidates and expand its portfolio into new disease states.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment